Twist Bioscience Corporation (NASDAQ:TWST) reported Q2 EPS of ($1.13), $0.15 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $45.25 million.
As of March 31, 2022, the company had $604.4 million in cash, cash equivalents and investments.